阻断基因组不稳定性可预防黑色素瘤对MAPK抑制剂治疗获得性耐药
在MAPK抑制剂(MAPKi)治疗后的转移性皮肤黑色素瘤患者及PDX小鼠中,获得性耐药基因组通过复杂基因组重排(CGR)和染色体外DNA(ecDNA)特异性扩增耐药驱动基因、非同源末端连接(NHEJ)和同源重组修复(HRR)基因。几乎所有敏感和获得性耐药基因组均携带广泛染色体碎裂区域。在黑色素瘤细胞系和PDX中,用DNA-PKCS抑制剂靶向NHEJ可在联合治疗早期通过缩小ecDNA和CGR来预防或延迟获得性MAPKi耐药。
要点
- 获得性耐药黑色素瘤通过ecDNA和CGR反复演化出耐药驱动和耐药特异性扩增子。
- DNA-PKCS抑制剂靶向NHEJ可在联合治疗早期缩小ecDNA和CGR,预防或延迟获得性MAPKi耐药。
- 染色体碎裂-ecDNA-CGR生物发生被提出作为耐药预防靶点。
核心结论
- 靶向基因组不稳定的成因可预防获得性耐药。
研究设计与样本
- 研究纳入接受MAPKi治疗的患者及携带患者来源异种移植(PDX)的小鼠,并用人黑色素瘤细胞系和PDX进行实验。
主要发现
- 获得性耐药转移性皮肤黑色素瘤基因组通过CGR和ecDNA特异性扩增耐药驱动基因、NHEJ和HRR基因。
- 几乎所有敏感和获得性耐药基因组均携带广泛染色体碎裂区域,这些区域突变负荷不成比例地高,并与ecDNA和CGR跨度显著重叠。
- ecDNA和CGR扩增子内的体细胞突变反复富集HRR特征,尤其在获得性耐药肿瘤中。
- 断点连接序列分析提示NHEJ对CGR和ecDNA形成所依赖的双链DNA断裂修复至关重要,与敏感性或耐药性无关。
- 在人类黑色素瘤细胞系和PDX中,DNA-PKCS抑制剂靶向NHEJ可在联合治疗早期通过缩小ecDNA和CGR来预防或延迟获得性MAPKi耐药。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Blocking cancer genomic instability may prevent tumor diversification and escape from therapies. We show that, after MAPK inhibitor (MAPKi) therapy in patients and mice bearing patient-derived xenografts (PDX), acquired resistant genomes of metastatic cutaneous melanoma specifically amplify resistance-driver, nonhomologous end-joining (NHEJ), and homologous recombination repair (HRR) genes via complex genomic rearrangements (CGR) and extrachromosomal DNAs (ecDNA). Almost all sensitive and acquired-resistant genomes harbor pervasive chromothriptic regions with disproportionately high mutational burdens and significant overlaps with ecDNA and CGR spans. Recurrently, somatic mutations within ecDNA and CGR amplicons enrich for HRR signatures, particularly within acquired resistant tumors. Regardless of sensitivity or resistance, breakpoint-junctional sequence analysis suggests NHEJ as critical to double-stranded DNA break repair underlying CGR and ecDNA formation. In human melanoma cell lines and PDXs, NHEJ targeting by a DNA-PKCS inhibitor prevents/delays acquired MAPKi resistance by reducing the size of ecDNAs and CGRs early on combination treatment. Thus, targeting the causes of genomic instability prevents acquired resistance. SIGNIFICANCE: Acquired resistance often results in heterogeneous, redundant survival mechanisms, which challenge strategies aimed at reversing resistance. Acquired-resistant melanomas recurrently evolve resistance-driving and resistance-specific amplicons via ecDNAs and CGRs, thereby nominating chromothripsis-ecDNA-CGR biogenesis as a resistance-preventive target. Specifically, targeting DNA-PKCS/NHEJ prevents resistance by suppressing ecDNA/CGR rearrangements in MAPKi-treated melanomas. This article is highlighted in the In This Issue feature, p. 799.
引用
- Dharanipragada P, Zhang X, Liu S, et al. Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma. Cancer Discov. 2023. PMID: 36700848. doi:10.1158/2159-8290.CD-22-0787
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。